Metraipolis › archive › dc_6ca439e55164

Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against shigellosis in a non-Human primate model (Macaca mulatta) — Europe PMC PMID:38091314

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/38091314
DOI
10.1371/journal.pone.0294021
License (as archived)
CC0-1.0
Archived
2026-10-07T11:30:36.567Z
SHA-256 of the archived text
ac5423fb9cda65bd01ca865183a2e7bd7d328eef5fa866c0ca5059a53f47c74a
Stable URL of this page
https://metraipolis.com/documento/dc_6ca439e55164

How to cite

Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against shigellosis in a non-Human primate model (Macaca mulatta) — Europe PMC PMID:38091314 — Europe PMC (en), https://europepmc.org/article/MED/38091314 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_6ca439e55164 (Metraipolis archive dc_6ca439e55164, sha256 ac5423fb9cda65bd01ca865183a2e7bd7d328eef5fa866c0ca5059a53f47c74a)
BibTeX
@misc{dc6ca439e55164,
  title = {Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against shigellosis in a non-Human primate model (Macaca mulatta) — Europe PMC PMID:38091314},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38091314},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_6ca439e55164; sha256 ac5423fb9cda65bd01ca865183a2e7bd7d328eef5fa866c0ca5059a53f47c74a},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38091314. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Infectious diarrhea is a World Health Organization public health priority area due to the lack of effective vaccines and an accelerating global antimicrobial resistance crisis. New strategies are urgently needed such as immunoprophylactic for prevention of diarrheal diseases. Hyperimmune bovine colostrum (HBC) is an established and effective prophylactic for infectious diarrhea. The commercial HBC product, Travelan® (Immuron Ltd, Australia) targets multiple strains of enterotoxigenic Escherichia coli (ETEC) is highly effective in preventing diarrhea in human clinical studies. Although Travelan® targets ETEC, preliminary studies suggested cross-reactivity with other Gram-negative enteric pathogens including Shigella and Salmonella species. For this study we selected an invasive diarrheal/dysentery-causing enteric pathogen, Shigella, to evaluate the effectiveness of Travelan®, both in vitro and in vivo. Here we demonstrate broad cross-reactivity of Travelan® with all four Shigella spp. (S. flexneri, S. sonnei, S. dysenteriae and S. boydii) and important virulence factor Shigella antigens. Naïve juvenile rhesus macaques (NJRM) were randomized, 8 dosed with Travelan® and 4 with a placebo intragastrically twice daily over 6 days. All NJRM were challenged with S. flexneri 2a strain 2457T on the 4th day of treatment and monitored for diarrheal symptoms. All placebo-treated NJRM displayed acute dysentery symptoms within 24-36 hours of challenge. Two Travelan®-treated NJRM displayed dysentery symptoms and six animals remained healthy and symptom-free post challenge; resulting in 75% efficacy of prevention of shigellosis (p = 0.014). These results strongly indicate that Travelan® is functionally cross-reactive and an effective prophylactic for shigellosis. This has positive implications for the prophylactic use of Travelan® for protection against both ETEC and Shigella spp. diarrheal infections. Future refinement and expansion of pathogens recognized by HBC including Travelan® could revolutionize current management of gastrointestinal infections and outbreaks in travelers' including military, peacekeepers, humanitarian workers and in populations living in endemic regions of the world.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2023 (prima pubblicazione 2023-12-13).
Identificativi: PMID 38091314 · PMCID PMC10718440 · DOI 10.1371/journal.pone.0294021.
Descrittori MeSH principali: Shigella; Dysentery, Bacillary; Dysentery; Enterotoxigenic Escherichia coli.
Pagina: https://europepmc.org/article/MED/38091314 — https://doi.org/10.1371/journal.pone.0294021. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-07T11:17:30.971Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.